Takeda Pharmaceutical Company Limited

Tomoaki Hasui

Masato Yoshikawa

Minoru Nakamura

Takahiko Taniguchi

Keisuke Imamura

Eiji Honda

Kasei Miura

Makoto Kamata

Jun Kunitomo

Shinji Nakamura

Tatsuki Koike

Haruhi Ando

Satoshi Mikami

Eiji Kimura

Tohru Yamashita

Makoto Fushimi

Haruhi Kamisaki

Shinkichi Suzuki

Izumi Nomura

Shotaro Miura

Xin Liu

Masami Yamada

Hidekazu Tokuhara

Toshihiro Imaeda

Yoshiteru Ito

Joseph Raker

Toshiya Nishi

Hiromi Fukuda

John Frederick Quinn

Yuichi Kajita

Kazuaki Takami

Takenori Hitaka

Masaki Daini

Atsuko Ochida

Shuhei Ikeda

Shinji Morimoto

Christer Halldin

Hironori Kokubo

Fatoumata Camara

Hiroyuki Kakei

Sachie Takashima

Akihiro Takano

Vladimir Stepanov

Yi Wang

Norio Oyabu

Fumie Yamaguchi

Chunxiang Wang

Toru Yamashita

Shogo Hashizume

The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Heterocyclic compounds

Substituted pyrido[1,2-a]pyrimidines and pyrazino[1,2-a]pyrimidines for enhancing AMPA receptor function

An object of the present invention is to provide a compound having a superior CH24H inhibitory action, which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. The present invention relates to a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof.

Heterocyclic compounds having cholesterol 24-hydroxylase activity

The present invention relates to a compound represented by the formula (I), which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. In the formula (I), each symbol is as defined in the specification. 

Heterocyclic compound

The present invention provides radiolabeled compounds useful as radiotracers for quantitative imaging of PDE10A in mammals. The compound of the present invention is represented by the formula (I): wherein each symbols are as defined in the specification. 

Radiolabeled compounds and their use as radiotracers for quantitative imaging of phosphodiesterase (PDE10A) in mammals

The present invention provides a compound or a salt thereof useful for an agent for the prophylaxis or treatment of neurodegenerative disease and the like. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia or so on represented by the formula (I): 

Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors

A compound having PDE inhibitory represented by formula (1), W-W(1), wherein (i) Wis and Wis (ii) Wis and Wis or (iii) Wis and Wis or a pharmaceutically acceptable salt thereof; and a method of treating or preventing schizophrenia.

Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors

The present invention provides a compound represented by the formula (1): wherein each symbol is as defined in the specification, or a salt thereof, a prodrug of the compound or a salt thereof, a medicament containing the compound or a salt thereof, the medicament which is a phosphodiesterase 10A inhibitor, and a medicament which is for preventing or treating schizophrenia.

The present invention provides a compound having a superior PDE10A inhibitory action and use thereof. The compound is a compound represented by the following formula (I): wherein each symbol is as defined in the present specification, or a salt thereof.

Condensed heterocyclic compound

The present invention provides a compound which has the effect of PDE 10A inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound represented by the formula (1'): wherein, Ring A&#x2032; represents an optionally substituted pyridine ring, an optionally substituted pyridazine ring, a pyrimidine ring, or 10 a pyrazine ring, R1&#x2032; represents (1) wherein, Rrepresents an optionally substituted phenyl group, or an optionally substituted 5- to 10-membered heterocyclic group, Ring B2 represents a bond, &#x2014;S&#x2014;, -0-, &#x2014;CO&#x2014;, an optionally substituted methylene group, or &#x2014;NR&#x2014; (Rrepresents a hydrogen atom, or an optionally substituted Calkyl group), and Ring Brepresents an optionally further substituted 6- to 10-membered aromatic hydrocarbon ring, or an optionally further substituted 5- to 10-membered aromatic heterocyclic ring, or alternatively, L&#x2032; and Rmay be taken together to form an optionally substituted bicyclic or tricyclic fused heterocyclic group, or (2), wherein, Rrepresents an optionally substituted phenyl group, or an optionally substituted 5- to 10-membered heterocyclic group, Ring Brepresents an optionally substituted benzene ring, an optionally substituted pyridine ring, an optionally substituted pyrimidine ring, an optionally substituted pyrazine ring, or an optionally substituted pyridazine ring, Ring D&#x2032; represents an optionally further substituted 5- or 6-membered ring, Rrepresents a hydrogen atom, or a substituent, X&#x2032; represents &#x2550;N&#x2014; or &#x2550;CR&#x2014;(Rrepresents a hydrogen atom, or a substituent), - - - - - represents that Rand Rmay form, taken together with the carbon atom and the nitrogen atom to which they are each adjacent, an optionally substituted 5- to 7-membered ring when.X&#x2032; is &#x2550;CR, or a salt thereof.

Fused heterocyclic compounds

The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia. The compound is represented by the formula (I): wherein the symbols are defined in the specification.

Provided is a compound having a PDE10A inhibitory action, and useful as a medicament for the prophylaxis or treatment of mental diseases such as schizophrenia and the like, and the like. A compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.

Fused heterocyclic ring compound

Fused heterocyclic compounds as phosphodiesterases (PDEs) inhibitors

Growing community of inventors

Kanagawa, Japan

Tomoaki Hasui